Immune-related GFAP-Astrocytopathy under PD-1 inhibition: A case report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Immune checkpoint inhibitors have substantially improved survival in advanced melanoma but are also associated with immune-related adverse events. Such events can affect any organ, including the central and peripheral nervous systems. Neurological adverse events are rare and often underrecognized. We report the case of a 53-year-old woman with melanoma who developed a severe neurological adverse event after treatment with the PD-1 inhibitor nivolumab. We describe a rare case of nivolumab-associated glial fibrillary acidic protein astrocytopathy and highlight the diagnostic challenges, therapeutic considerations, and importance of early recognition of these potentially severe neurological adverse events.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Autoimmune Neurological Disorders and Treatments
Glioma Diagnosis and Treatment
Publication details
- Journal / source
- EJC Skin Cancer
- Volume
- 4
- Pages
- 101136–101136
- Publication date
- 1 January 2026
- Language
- EN